Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1320Neoplasms 983Carcinoma, Non-Small-Cell Lung 858Prostatic Neoplasms 723Colorectal Neoplasms 662Lung Neoplasms 548Leukemia, Myeloid, Acute 475Neoplasm Metastasis 431Pancreatic Neoplasms 418Carcinoma, Hepatocellular 406Multiple Myeloma 397Ovarian Neoplasms 391Stomach Neoplasms 378Recurrence 365Squamous Cell Carcinoma of Head and Neck 325Melanoma 293Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Head and Neck Neoplasms 263Glioblastoma 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 233Lymphoma 227Esophageal Neoplasms 222Rectal Neoplasms 221Sarcoma 211Carcinoma, Renal Cell 203Colonic Neoplasms 193Lymphoma, Large B-Cell, Diffuse 191

Interventions

Cobicistat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × BRAF V600E Mutation × Clear all
NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡